Follow
Sai-Hong Ignatius Ou
Title
Cited by
Cited by
Year
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
51022010
Crizotinib in ROS1-rearranged non–small-cell lung cancer
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
18852014
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ...
New England Journal of Medicine 377 (9), 829-838, 2017
18622017
ROS1 rearrangements define a unique molecular class of lung cancers
K Bergethon, AT Shaw, SH Ou, R Katayama, CM Lovly, NT McDonald, ...
J Clin Oncol 30 (8), 863-870, 2012
17712012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ...
The lancet oncology 13 (10), 1011-1019, 2012
14362012
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
10862011
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant LUAC
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
9412018
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs
SH Ou, F Wu, D Harrich, LF García-Martínez, RB Gaynor
Journal of virology 69 (6), 3584-3596, 1995
8601995
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 …
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ...
The lancet oncology 16 (7), 830-838, 2015
7922015
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG …
SM Gadgeel, L Gandhi, GJ Riely, AA Chiappori, HL West, MC Azada, ...
The Lancet Oncology 15 (10), 1119-1128, 2014
7112014
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
J Hallin, LD Engstrom, L Hargis, A Calinisan, R Aranda, DM Briere, ...
Cancer discovery 10 (1), 54-71, 2020
6862020
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ...
Annals of Oncology 30 (8), 1321-1328, 2019
6662019
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
SHI Ou, JS Ahn, L De Petris, R Govindan, JCH Yang, B Hughes, H Lena, ...
Journal of clinical oncology 34 (7), 661-668, 2016
6662016
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1 …
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
6622017
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
AT Shaw, L Gandhi, S Gadgeel, GJ Riely, J Cetnar, H West, DR Camidge, ...
The lancet oncology 17 (2), 234-242, 2016
6562016
Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases
DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ...
Journal of Clinical Oncology 33 (17), 1881, 2015
6382015
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET InhibitorsMET Exon 14 Alterations Confer …
GM Frampton, SM Ali, M Rosenzweig, J Chmielecki, X Lu, TM Bauer, ...
Cancer discovery 5 (8), 850-859, 2015
6352015
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
BJ Solomon, B Besse, TM Bauer, E Felip, RA Soo, DR Camidge, R Chiari, ...
The Lancet Oncology 19 (12), 1654-1667, 2018
5812018
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung CancerALK-Positive Tumors Lack EGFR or KRAS …
JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ...
Clinical cancer research 19 (15), 4273-4281, 2013
5552013
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
JCH Yang, JY Shih, WC Su, TC Hsia, CM Tsai, SHI Ou, CJ Yu, GC Chang, ...
The lancet oncology 13 (5), 539-548, 2012
4822012
The system can't perform the operation now. Try again later.
Articles 1–20